Press Releases ESSA Pharma Inc.

Equities

EPIX

CA29668H7085

Market Closed - Nasdaq Other stock markets 21:00:00 10/05/2024 BST			5-day change	1st Jan Change
6.24 ^USD	-0.16%		-9.30%	-5.45%

03-06	Transcript : ESSA Pharma Inc. - Shareholder/Analyst Call
03-06	Norway's wealth fund pushes for more women on emerging market company boards	RE

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

ESSA Pharma to Present at the 2024 Bloom Burton & Co. Healthcare Investor Conference	04-09	PR
ESSA PHARMA INC. REPORTS RESULTS OF ANNUAL GENERAL MEETING OF SHAREHOLDERS	03-08	PR
ESSA PHARMA INC. REPORTS RESULTS OF ANNUAL GENERAL MEETING OF SHAREHOLDERS	03-08	AQ
ESSA Pharma : Passive Foreign Investment Company Statement	02-27	PU
ESSA Pharma: Fiscal Q1 Earnings Snapshot	02-13	AQ
ESSA Pharma Provides Corporate Update and Reports Financial Results for Fiscal First Quarter Ended December 31, 2023	02-13	AQ
ESSA Pharma to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference	02-06	PR
ESSA Pharma Presents Updated Phase 1 Masofaniten Clinical Data at the 2024 ASCO Genitourinary Cancers Symposium	01-26	AQ
ESSA Pharma Presents Updated Phase 1 Masofaniten (EPI-7386) Clinical Data at the 2024 ASCO Genitourinary Cancers Symposium	01-25	PR
ESSA Pharma: Fiscal Q4 Earnings Snapshot	12-12	AQ
ESSA Pharma Provides Corporate Update and Reports Financial Results for Fiscal Fourth Quarter and Year Ended September 30, 2023	12-12	AQ
ESSA Pharma to Present at the Piper Sandler 35th Annual Healthcare Conference	11-21	PR
ESSA Pharma to Present at the Jefferies London Healthcare Conference	11-08	PR
ESSA Pharma Enters into At-The-Market Equity Offering Sales Agreement	11-06	PR
ESSA Pharma Enters into At-The-Market Equity Offering Sales Agreement	11-06	AQ
ESSA Pharma : Enters into At-The-Market Equity Offering Sales Agreement - Form 8-K	11-06	PU
ESSA Pharma Presents Updated Phase 1 Masofaniten Clinical Data at the 30th Annual Prostate Cancer Foundation Scientific Retreat	27/10/23	AQ
ESSA Pharma Presents Updated Phase 1 Masofaniten (EPI-7386) Clinical Data at the 30th Annual Prostate Cancer Foundation Scientific Retreat	26/10/23	PR
ESSA Pharma Presents Updated Phase 1 Masofaniten (EPI-7386) Clinical Data at the 30th Annual Prostate Cancer Foundation Scientific Retreat	26/10/23	AQ
ESSA Pharma Presents Updated Phase 1 Masofaniten Clinical Data at the European Society of Medical Oncology 2023 Congress	23/10/23	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases ESSA Pharma Inc.

Equities

EPIX

CA29668H7085

Press Releases

Filters